Prebiotics and Immune Function in Middle Aged Humans
Investigation of the Effects of a Prebiotic Supplement on Immune Function in Healthy Human Adults
調査の概要
詳細な説明
Prebiotics are naturally occurring carbohydrates found in a variety of edible plants. They are not digested by mammalian enzymes, and so reach the gut intact, where they are fermented by some species of intestinal bacteria. This fermentation is thought to have several benefits for the host including improving the immune response. Inulin-type fructans (oligofructose and inulin) are classified as prebiotics. Inulin is found naturally in significant amounts in a variety of plants foods, such as bananas, leeks, onions, artichokes, wheat and chicory. Synergy1 is a prebiotic preparation produced by Beneo-Orafti, and containing a mixture of oligofructose and inulin derived from chicory. Fructooligosaccharides including Synergy1 are widely used by the food industry and are commonly found as a source of insoluble fibre in many biscuit, bakery, cereal and dairy products.
There is increasing evidence that the changes in the intestinal microflora that occur with the consumption of fructooligosaccharides can modulate immune parameters, not only in the gut-associated lymphoid tissue, but also secondary lymphoid tissues and the peripheral circulation. Much of the evidence for beneficial effects of fructooligosaccharides on immune function comes from animal models e.g. rats, mice, dogs and pigs. Results from these studies show that the innate and adaptive immune systems of both the gut associated lymphoid tissue and the systemic immune system can be modified by fructooligosaccharides. However, there are few human studies so far which have investigated the effects of prebiotics on immune function, and these studies mostly rely on systemic markers of immunity. The results show little effect of fructooligosaccharides on innate immune function, but mixed results are reported regarding the adaptive immune system, suggesting that there may by improvement on this aspect of immunity with increased intake of fructooligosaccharides. The small number of published human studies led Watzl et al. (2005) to suggest that more human studies are needed to find out whether inulin and/or oligofructose have the potential to modulate systemic immunity in well-nourished individuals.
There are numerous methods available for assessing the human immune response. These have been evaluated by a panel of European experts (Albers et al. 2005). Based on its biological relevance, sensitivity and practical feasibility, response to vaccination was identified by this panel as the gold standard for measuring the functioning of the immune system in vivo (Albers et al. 2005). A small number of studies have studied the effect of fructooligosaccharides on the human immune response using vaccination response as the outcome, but only four of these examined fructooligosaccharides in the absence of other additional nutrients and of these two studies were in infants. Thus, the number of studies examining the immunologic impact of fructooligosaccharides in adult humans and using the gold standard outcome is very limited. From a public health perspective, it would be of importance, if fructooligosaccharides can improve immune function especially in older adults who are at risk of age-related immune decline. Thus, we propose to use a commercially available influenza vaccine (Imuvac®) to stimulate the immune response in healthy human adults, and to use this to assess the effect of a well defined prebiotic preparation commonly used in the food industry (Synergy1).
研究の種類
入学 (実際)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Southampton、イギリス、SO16 6YD
- University of Southampton
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged 45-65 years
- Body mass index 20 to 32 kg/m2.
- Not consuming probiotic supplements, yoghurts, drinks or other foods
- Not consuming prebiotic supplemented drinks or foods
- In general good health
- No antibiotic use in the 2 months prior to entering the study or during the study
- Not been vaccinated with the current season's influenza vaccine
- Being able to provide written informed consent
Exclusion Criteria:
- Aged < 45 or > 66 years
- Body mass index < 20 or > 32 kg/m2.
- Being diabetic (type 1 or type 2)
- Displaying manifestations of allergy - asthma, hay-fever, dermatitis - or being treated for these
- Being egg allergic
- Use of any prescribed medicine (unless deemed to be acceptable by the PI)
- Suffering from any infectious illness
- Chronic gastrointestinal problems (e.g. IBD, IBS, cancer)
- Recent blood donation
- Participation in another clinical trial
- Use of prebiotic or probiotic supplements, foods or drinks
- Consuming vitamin, mineral or oil supplements
- Previously vaccinated with the influenza vaccine being used.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:マルトデキストリン
|
プラセボとしてのマルトデキストリン
他の名前:
|
|
実験的:Prebiotic
Inulin type fructooligosaccharides
|
Inulin type fructooligosaccharides
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Serum anti-vaccine antibody concentrations
時間枠:Weeks 2 and 4 post-vaccination
|
Weeks 2 and 4 post-vaccination
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Serum total antibody (IgG, IgA, IgM) concentrations
時間枠:Weeks -4, 0, 2 and 4 with respect to vaccination
|
Weeks -4, 0, 2 and 4 with respect to vaccination
|
|
Innate immune responses - neutrophil and monocyte phagocytosis and respiratory burst
時間枠:Weeks -4, 0, 2 and 4 with respect to vaccination
|
Weeks -4, 0, 2 and 4 with respect to vaccination
|
|
Ex vivo T lymphocyte responses to mitogen (activation, proliferation and cytokine production)
時間枠:Weeks -4, 0, 2 and 4 with respect to vaccination
|
Weeks -4, 0, 2 and 4 with respect to vaccination
|
|
Ex vivo T lymphocyte responses to vaccine (activation, proliferation and cytokine production)
時間枠:Weeks 0, 2 and 4 with respect to vaccination
|
Weeks 0, 2 and 4 with respect to vaccination
|
|
Ex vivo natural killer cell activity
時間枠:Weeks -4, 0, 2 and 4 with respect to vaccination
|
Weeks -4, 0, 2 and 4 with respect to vaccination
|
|
Faecal microflora
時間枠:Weeks -4 and 0 with respect to vaccination
|
Weeks -4 and 0 with respect to vaccination
|
|
Salivary IgA concentration
時間枠:Weeks -4, 0, 2 and 4 with respect to vaccination
|
Weeks -4, 0, 2 and 4 with respect to vaccination
|
協力者と研究者
捜査官
- 主任研究者:Philip C Calder, PhD、University of Southampton
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- RHMNUT0055
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。